X4 Pharmaceuticals

234 articles about X4 Pharmaceuticals

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2022

  4/1/2022

  X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, announced that, on March 31, 2022 the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

  3/17/2022

  X4 Pharmaceuticals, Inc. reported financial results for the fourth quarter and twelve months ended December 31, 2021, and provided a corporate update.

• X4 Pharmaceuticals to Announce Fourth Quarter 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022

  3/8/2022

  X4 Pharmaceuticals, Inc. announced that it will report its financial results for the fourth quarter ended December 31, 2021, and provide an update on recent business highlights, on March 17, 2022.

• X4 Pharmaceuticals to Present at March Investor Conferences

  3/3/2022

  X4 Pharmaceuticals, Inc. today announced that management will participate in a panel at the 42nd Annual Cowen Healthcare Conference on Monday, March 7, 2022 and in a fireside chat at the 32 nd Annual Oppenheimer Healthcare Conference on Tuesday, March 15, 2022.

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 01, 2022

  3/1/2022

  X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, announced that, on February 28, 2022 the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 02, 2022

  2/2/2022

  X4 Pharmaceuticals, Inc. announced that, on January 31, 2022, the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference

  1/19/2022

  X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that management will participate in a fireside chat at B. Riley Securities Oncology Investor Conference.

• 

  CEO to CEO: Tips for First-time Founders

  1/11/2022

  BioSpace picked the brains of 10 biotech CEOs and founders, to solicit their advice for first-time founders.
• 

  Biopharma Executive Perspectives on 2022

  1/10/2022

  BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade.

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 05, 2022

  1/5/2022

  X4 Pharmaceuticals, Inc. announced that, on December 31, 2021, the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• 

  Clinical Catch-Up: December 11-17

  12/20/2021

  It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.

• X4 Pharmaceuticals Presents New Clinical and Scientific Data at 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

  12/13/2021

  X4 Pharmaceuticals, Inc. today highlighted key takeaways from three clinical and scientific posters presented over the weekend at the American Society of Hematology (ASH) Annual Meeting, taking place both virtually and in person in Atlanta, GA from December 11-14, 2021.

• X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

  12/11/2021

  X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with immune system dysfunction, announced new positive efficacy and safety data from the ongoing Phase 1b clinical trial of its lead candidate mavorixafor, in combination with ibrutinib, for patients with Waldenström’s macroglobulinemia and confirmed MYD88 and CXCR4 mutations.

• X4 Pharmaceuticals to Host Virtual Seminar “Understanding Primary Immunodeficiencies” to Highlight Broadening Market Opportunities for Mavorixafor

  12/2/2021

  X4 Pharmaceuticals, Inc, today announced that it will host a virtual seminar “Understanding Primary Immunodeficiencies” on Thursday, December 16, 2021 at 8:30 a.m. EST,

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 01, 2021

  12/1/2021

  X4 Pharmaceuticals, Inc. announced that, on November 30, 2021, the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• X4 Pharmaceuticals to Participate in Stifel’s Virtual Healthcare Conference

  11/10/2021

  X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, announced that management will participate in a fireside chat at Stifel’s Virtual Healthcare Conference on Wednesday, November 17, 2021.

• X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data; Company Reports Third Quarter Financial Results

  11/4/2021

  X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, reported financial results for the third quarter and nine months ended September 30, 2021.

• X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 01, 2021

  11/1/2021

  X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, announced that, on October 29, 2021, the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

• X4 Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021

  10/25/2021

  X4 Pharmaceuticals, Inc. today announced that it will report its financial results for the third quarter ended September 30, 2021, and provide an update on recent business highlights, on November 4, 2021.

• 

  BioSpace Movers & Shakers, Oct. 22

  10/22/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.